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Abstract 
Aim: Develop modified dextran nanoparticles showing potential to assist with drug permeation 
across BBB for the delivery of neuropeptides. 
Methods: Nanoparticles loaded by emulsification with model macromolecular actives were 
characterized in terms of stability, cytotoxicity and drug release behavior. Peptide-loaded 
nanoformulations were tested in an in-vivo trout model and in food-deprived mice. 
Results: Nanoformulations loaded with model peptides show good stability and appear nontoxic  in 
low concentration against human brain endothelial cells. They were found to preserve the bioactivity 
of loaded peptides (angiotensin II) as demonstrated in-vivo using a trout model, and to induce a 
reduction in food consumption in mice when loaded with an anorexigenic octaneuropeptide. 
Conclusion: Octylglyceryl dextran-graft-poly(lactic) acid nanoparticles formulated by 
emulsification demonstrate potential for peptide delivery. 
Keywords nanoparticles; dextran; neuropeptides; drug delivery; brain. 
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Introduction 
The blood-brain barrier (BBB) continues to represent a major challenge for drug delivery as it 
prevents successful therapy with many neuropotent molecules including antibiotics, neuropeptides 
and antineoplastics [1-3]. This is exacerbated by the fact that historically relative little research has 
been directed towards enhancing drug delivery to the brain in comparison to the effort invested in 
drug discovery and development [4]; such imbalance is a major hurdle to treating CNS disorders, as 
most drugs developed have little access to their active sites in the brain due to the BBB [5]. 
At the neurovascular unit level, the BBB infrastructure lies mainly in the endothelial cells of the brain 
capillaries in combination with pericytes and astrocytes, and creates a physical transport and 
enzymatic barrier between the blood and the circulatory system that is necessary for regulating the 
internal environment of the brain (the composition of the extracellular fluid in the brain is maintained 
under constant and precise control independent of the composition of the blood, which helps to 
provide a stable environment for optimal neuronal function [6-8]. Such a barrier is very effective in 
preventing the uptake of most pharmaceuticals except for small hydrophilic molecules (< 150 Da) and 
some highly hydrophobic drugs (< 600 Da) that are able to diffuse through the endothelial cell 
membrane [9]. 
Various delivery strategies have been investigated historically in concerted efforts to overcome the 
BBB and enhance drug concentration in the brain through non-invasive methods. Osmotic opening of 
the tight junctions using hypertonic solutions is effective but problematic due to the high risk of 
potentially dangerous substances and pathogens also gaining access to the brain [10]. The re-design of 
existing drugs via chemical modification into lipophilic pro-drugs that can diffuse through the 
endothelial cells barrier (and convert back into the active drug once inside the brain) is limited to the 
number of active molecules open for such chemical modification, and the efficiency is drastically 
affected by the efflux pumps that eliminate the active drug [11]. An alternative approach exploits the 
endogenous transport system by employing existing BBB transporters (whose role is to transport 
molecules essential for brain function such as glucose, amino acids, certain peptides and proteins) to 
carry drug payloads across the barrier; it has been shown that it is possible to target these endogenous 
carrier systems by tagging neuroactives with antibodies or specific ligands [12]. 
Many recent research efforts have focused on the use of colloidal drug carriers such as liposomes and 
nanoparticles, which offer the advantage of easy conjugation with various ligands [13]. Among the 
various polymers investigated for the formulation of nanoparticles aimed at drug delivery to the brain, 
of particular interest are natural polysaccharides such as dextran, chitosan, cyclodextrins, starch and 
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cellulose, due to their biocompatibility, biodegradability and ease of chemical functionalization [14- 
15]. The structure of many polysaccharides offers the possibility of easy conversion into amphiphilic 
materials that can self-assemble into micro and nano structures, which can then act as optimal carriers 
for a variety of drugs. Common methods for the preparation of nanoparticles based on 
polysaccharides include emulsification followed by solvent evaporation, solvent diffusion, self- 
assembly, and/or dialysis [16-17]. 
Following from recent results suggesting that the assemblage of a drug-carrier system based on 
dextran that had been modified with alkylglyceryl moieties and the easily biodegradable poly(lactic 
acid) has potential to promote increased drug permeability towards the brain [18], we report here on 
the formulation and characterisation of octylglyceryl dextran-graft-poly(lactic acid) based 
nanoparticles loaded with model peptides via emulsification methods. Results of in vitro and in vivo 
investigations that were carried out to determine the potential of loaded peptides (angiotensin II and 
octaneuropeptide, a down-sized analogue of the octadecaneuropeptide ODN) to be delivered across 
the BBB are also reported. 
Methods 
Materials and equipment 
Fluorescein isothiocyanate-dextran (150 kDa), 4-dimethylaminopyridine (DMAP), human angiotensin 
II (ANG2), ferricytochrome C, superoxide dismutase, adenosine 3,5-cyclic monophosphate, 
hydrocortisone, fetal calf serum (FCS), bovine serum albumin (BSA), BCA assay, Hank's balanced 
salt solution (HBSS), phosphate-buffered saline (PBS), dextran (100 kDa), trehalose, Rhodamine B, 
Hoechst 33342, Triton X-100, NaOH solution (1 M), sodium dodecyl sulphate (SDS), and 
polyethylene glycol (PEG) 6 kDa were all purchased from Sigma-Aldrich, Gillingham, UK. 
Poly(vinyl alcohol) 16 kDa, L-glutamine, 2-mercaptoethanol, sodium pyruvate, MEM non-essential 
amino acids solution, Lab- ek eight-chamber glass slides, Corning matrigel basement membrane 
matrix phenol red free/DEV free, Dulbecco's modified eagle's medium (DMEM), antibiotic- 
antimycotic, and trypLE Express enzyme were purchased from Fisher Scientific, Loughborough,  UK. 
HUVEC pooled pre-screened EGM2, EGM bullet kit medium, and reagent pack subculture kits were 
obtained from Lonza, Tewkesbury, UK. Cell titer Aqueous One solution cell proliferation assay was 
purchased from Promega, Southampton, UK.RO-20-1724 and forskolin were sourced from Enzo Life 
Science, NY, USA. Poly(lactic acid) with free carboxyl group (PLA; MW 15 kDa) was obtained from 
Purac, Gorinchem, Netherlands. Octaneuropeptide (OP) was synthesised as previously described in 
the literature [19]. An Ultra Turrax IKA- 18 homogeniser was used for emulsification and a PolarStar 
Optima plate reader (BMG Labtech, Aylesbury UK) was employed for assay readings.
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Preparation of octylglyceryl modified dextran 
The synthesis of modified dextran was carried out as described in the literature [20], with some 
modifications. Briefly, dextran (2 g, 12.35 mmol glucose equivalent) was dissolved in anhydrous 
DMSO (150 mL), to which a solution of potassium tert-butoxide (1.38 g; 12.35 mmol) dissolved in 
anhydrous DMSO (50 mL) was added dropwise. The mixture was allowed to stir for 2 h before the 
dropwise addition of a solution of n-octyloxymethyloxirane (OX8; 12.6 mL; 63 mmol) in anhydrous 
DMSO (20 mL), then stirred for an additional 24 h at 40°C and followed by dialysis (MWCO 12-14 
kDa; 3 day) against deionised water (10 L; exchanged 3 times per day). The content of the dialysing 
membrane was washed with diethyl ether (3 × 150 mL) in a separating funnel; the traces of organic 
solvent were removed from the aqueous layer in a rotary evaporator under reduced pressure and the 
product was lyophilised to afford 2-hydroxy-3-(octyloxy)propoxy dextran (DEX-OX8; named here 
octylglyceryl modified dextran) as off-white powder. 
Synthesis of octylglyceryl-modified dextran-graft-poly(lactic) acid (DEX-OX8-PLA) 
Dicyclohexylcarbodiimide (0.225 g; 1.09 mmol) dissolved in anhydrous DMSO (20 mL) was added 
to a solution of PLA (8.75 g) in anhydrous DMSO (100 mL). The mixture was stirred for 30 min at 
room temperature and was gradually added to a solution of DEX-OX8 (3.5 g) and DMAP (0.11 g; 
0.90 mmol), both dissolved in anhydrous DMSO (150 mL) under stirring for 1 h. The reaction 
mixture was allowed to react for 24 h at room temperature with continuous stirring, and it was then 
filtered, dialysed for four days (against deionised water) and lyophilised. The obtained powder was 
washed with acetone and dried in a desiccator, then it was redispersed in water and finally lyophilised 
again to afford pure DEX-OX8-PLA as a fine, white powder. 
Formulation of peptide-loaded DEX-OX8-PLA nanoparticles via the double emulsification 
method 
DEX-OX8-PLA (40 mg) was dissolved in dichloromethane (DCM; 5 mL), BSA (9 mg) and peptide 
(1 mg; either ANG2 or OP) were dissolved separately in PBS (1 mL). The peptide solution was first 
emulsified with the polymer solution (DEX-OX8-PLA; 0.8% w/v) using an Ultra Turrax homogeniser 
(23,000 rpm; 3 min). A poly(vinylalcohol) solution (10 mL; 50 mg/mL; PVA, 16 kDa) was then 
added and the mixture was homogenised (23,000 rpm; 3 min) to form a water-in-oil-in-water (WOW) 
emulsion. Control nanoparticles were prepared using the same method except that the primary 
emulsion was formed with PBS alone (no peptide). The emulsions were stirred for 3 h (magnetic 
stirrer) to allow for solvent evaporation, and the nanoparticles were then collected by 
ultracentrifugation (50,000 rpm; 302,000 g; 30 min). 
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where: 
A - mass of protein / peptide entrapped (mg)  
B - mass of the loaded nanoparticles (mg)  
C - initial mass of protein / peptide used (mg) 
Characterisation of DEX-OX8-PLA nanoparticles 
Nanoparticles were re-dispersed in deionised water by sonication (20 min) and analysed by Dynamic 
Light Scattering using a Malvern Zetasizer Nano ZS instrument and by Nanoparticle Tracking 
Analysis using a Nanosight LM10 instrument equipped with a 532 nm green laser module. The 
stability of nanoparticle suspensions was tested by repeating the measurements after 24 h. The zeta 
Formulation of peptide-loaded DEX-OX8-PLA nanoparticles using the solid-in-oil-in-water 
dispersion method 
BSA (9 mg) and peptide (1 mg; either ANG2 or OP) were mixed with polyethylene glycol (PEG; 50 
mg) and dissolved in deionised water (1 mL) by vortexing; the solution was frozen in liquid nitrogen 
and freeze-dried overnight to afford solid protein nanospheres that were further entrapped into DEX-
OX8-PLA particles as follows. DEX-OX8-PLA (40 mg) was added to DCM (4 mL), followed by 
vortexing and allowing the mixture to dissolve completely on a shaker for 1 h. The protein 
nanospheres (the above lyophilisate of protein and PEG) were added to the polymer solution and the 
mixture was homogenised (3 min; 23,000 rpm). PVA solution (10 mL; 50 mg/mL) was then added 
and the mixture was further homogenised (3 min; 23,000 rpm) and then magnetically stirred for 3 h to 
evaporate the organic solvent. The suspension was then ultracentrifuged (50,000 rpm; 302,000 g; 30 
min) and the supernatant removed; the collected nanoparticles were dried in vacuo. Blank control 
nanoparticles (with PEG but without peptide/protein) were prepared using the same procedure. 
Determination of nanoparticle entrapment efficiency (EE%) 
The amount of BSA and peptide (either ANG2 or OP) entrapped was determined by dissolving 
nanoparticles (4 mg) in a DMSO/SDS/NaOH solution and by using a BCA assay. By determining the 
BSA or peptide concentration in the solution of the dissolved nanoparticles it was possible to calculate 
the amount of protein and then calculate the entrapment efficiency (EE%) and the loading capacity of 
the nanoparticles (as degree of loading, DL%) using equations 1 and 2: 
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potential of nanoparticles was determined via electrophoretic mobility measurements (EPM) using the 
same Malvern Zetasizer Nano ZS instrument. 
Investigations of the effect of process parameters on the ANG2-loaded nanoparticle size and 
ANG2 entrapment efficiency using the WOW method 
The effect of several variables such as polymer, protein and PVA concentration, and the duration and 
speed of homogenization on the characteristics of the ANG2 loaded nanoparticles was investigated. 
Polymer concentrations in the range 0.5 to 1.5% (w/v), protein concentrations in the range 10 to 30 
mg/mL, and PVA concentrations in the range 30 to 50 mg/mL were investigated. Homogenization 
speed was varied between 15,000 and 23,000 rpm for either 1 or 3 min. 
Studies of ANG2 release from DEX-OX8-PLA nanoparticles 
Nanoparticles (4 mg) were suspended in PBS (1 mL) and incubated at 37 °C with continuous orbital 
shaking. At different time points, the nanoparticles were centrifuged down (13,000 rpm; 14,800 g; 30 
min) and the supernatant was collected for HPLC analysis (peptide content) and then replaced with 
fresh PBS. 
Biological activity of the ANG2 released from nanoparticles 
HUVEC cells were cultured in 24 well plates in EGM-2 medium, which was then removed and 
replaced with ANG2 aqueous solution (200 µl) of different concentrations (either 0.05, 0.01, or 0.1 
µg/mL) and ferricytochrome C (200 µl; 140 µM). The amount of superoxide anion produced was 
monitored after incubation at 37 ˚C at different time points (30, 60, 90 and 120 min) using a 
ferricytochrome C reduction assay(measuring the absorbance at 550 nm). . To determine the 
bioactivity of the loaded and then released ANG2, nanoparticles were added to the HUVEC cells at a 
predetermined concentration that would release 0.01 µg/mL of ANG2 in the medium. The amount of 
superoxide anion released was monitored and compared to both positive and negative controls. 
Cytotoxicity investigations of ANG2 loaded DEX-OX8-PLA nanoparticles using bEnd3 and 
hCMEC/D3 cells 
Mouse brain endothelial cells (bEnd3) were seeded in 96 well plates at a density of 25,000 cells/well 
in modified DMEM (10% FCS, 2mM L-glutamine, 5µM sodium pyruvate, 1% non-essential amino 
acids). Human cerebral microvascular endothelial cells (hCMEC/D3) immortalised with 
hTERT/SV40 Lagre T antigen (Institute Cochin, INSERM, Paris, France) were cultured in EGM-2 
media and treated following the same protocol. The cells were left to attach to the plates overnight 
and the media was replaced by fresh one containing ANG2 loaded DEX-OX8-PLA DEX-OX8 
nanoparticles suspended in deionised water (1 mg/mL). At different time points, an MTT assay was 
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carried out to measure the cell viability; following the addition of the MTT assay reagent (20 µL), the 
plates were incubated for 2 h at 37 ˚C and the absorbance at 490 nm was measured. 
bEnd3 cell uptake studies using Rhodamine B and ANG2 loaded nanoparticles 
bEnd3 cells were seeded onto Lab- ek eight-chamber glass slides at a density of 5 × 104 cells per well 
and left to attach overnight in 400 µL of modified DMEM, as above. ANG2 loaded DEX-OX8-PLA 
nanoparticles were labelled with Rhodamine B by mixing a nanoparticle suspension with Rhodamine 
B solution at a weight ratio nanoparticle:Rhodamine of 1:1; the nanoparticles were then recovered 
through centrifugation (13,000 rpm; 14,800 g; 1 h), re-suspended in growth medium, and used to 
incubate the bEnd3 cells cultured on the Lab- ek glass slides. Control slides were incubated with 
media. After 3 h, the media was recovered and the cells were washed with PBS, fixed with 
paraformaldehyde (4.0%, w/v) at 4 °C for 10 min, permeabilised with Triton X-100 (0.1%, v/v) for 20 
min and finally stained with Hoechst 33342 (5.0 µg/mL) for 40 min at room temperature. The cells 
were then visualised using a confocal microscope (LSM 710, ZEISS; 405 nm for Hoechst, 543 nm for 
Rhodamine B). 
Investigations of the effect of intra-arterial injection of ANG2 loaded nanoparticles on the 
blood pressure and heart rate in an in vivo trout model 
Animal handling and experimental protocols were approved by the local ethical committee (CEFEA 
02142.01). Non anaesthetised rainbow trout (Oncorhynchus mykiss) were prepared with two 
electrocardiographic (ECG) AgCl electrodes and a dorsal aorta cannula. Either 50 µL of vehicle 
(Ringer’s solution) as negative control, free ANG2 (50 pmol dose) as positive control, or a suspension 
of ANG2-loaded DEX-OX8-PLA nanoparticles (at an equivalent ANG2 loaded dose of 50 pmol) 
were injected intra-arterially through the dorsal aorta. The effects of the released ANG2 from the 
nanoparticles on the heart rate and blood pressure of the trout were recorded using standardized 
electronic devices and analysed using a PowerLab 4/30 data acquisition system (ADInstruments, 
Oxford, England) and LabChart Pro software (v.7.0; ADInstruments, Oxford, England) [21] and 
compared to that of the controls. 
Investigations of the effect of intra-venous injection of OP loaded nanoparticles on the food 
intake of mice 
Animal manipulations were performed according to the European Community Council Directive 
(86:609:EEC), were approved by the local Ethical Committee (authorization numbers: N/10-04-04-12 
and N/13-04-04-15) and were conducted by authorized investigators. Male Swiss albinos CD1 mice 
(Iffa-Credo/Charles River, Saint-Germain-sur-l’Arbresle, France), weighing 22–25g, were housed 20 
in Makrolon cages, with free access to standard semisynthetic laboratory diet (U.A.R., Villemoisson- 
sur-Orge, France) and tap water. The animals were kept in a ventilated room at a temperature of 22±1 
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°C under a 12h light/dark cycle. All the experiments were carried out between 9am and 6pm in testing 
rooms adjacent to the animal rooms. Two days before the experiments, mice were anesthetized with 
isoflurane (5% for the induction and 1.75% during the surgery) and the tail vein was canulated with a 
0.25mm external diameter nylon catheter filled with saline and closed by a top. Mice were then 
isolated in individual cages with free access to water and the pellets of food laid down the floor of the 
cages, in order to make the animals accustomed to the test conditions. Fifteen hours before (6:00 p.m. 
to 9:00 a.m.), animals were totally deprived of food but had ad libitum access to water. Then, mice 
received a ≈5g weighed food pellet deposited on the floor of the cage 10 min after intravenous (100 
µL) administration of saline (0.9% NaCl) or OP-loaded NPs (equivalent to 10 µg of OP) through the 
tail catheter during 4 days. Thereafter, the pellet was briefly (<20s) removed with forceps and 
weighed every 3h, for 9h and a 6-day period. 
Statistical treatment of data 
All results were presented as mean ± standard error of the mean, with a minimum number of 
replicates n = 3. Anova with Tukey post-hoc tests were used for normally distributed data, 
alternatively non-parametric K independent samples test with Mann-Whitney tests were carried out; 
multiple T-tests, with the level of significance set at 0.05, were also carried out using SPSS 21 
software. 
Results and discussion 
The chemical functionalisation of dextran with 2-[(octyloxy)methyl]oxirane followed by 
grafting with PLA were carried out as previously reported in the literature [18, 20], with some 
adjustments. 
1
H-NMR data confirming the chemical modification of dextran (Figure 1) 
revealed the resulting material had  a degree of substitution with OX8 (defined as the number of 
octylglyceryl chains attached to 100 glucose residues) of 28.4 %, and a degree of grafting with 
PLA (defined as the number of lactic acid units grafted, as PLA polymer chains, per 100 
glucose residues) of 163.9 %. 
Figure 1 
Employed as model protein and peptides, BSA, ANG2 and OP were loaded into DEX-OX8-PLA 
polymer nanoparticles using two alternative methods, which combine emulsification with solvent 
evaporation. In the double emulsion method (WOW), reported as suitable for peptide loading into 
nanoparticles [22, 23], an initial W/O emulsion of the model active aqueous solution in an organic 
solution of the polymer was further emulsified in aqueous PVA. In the solid/oil/water dispersion 
method (SOW, previously employed to load proteins into microparticles [24]), the model drug was 
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first loaded by phase separation into small nanospheres, which were subsequently dispersed into an 
organic solution of the polymer, and the resulting primary solid-in-oil dispersion was further 
emulsified in aqueous PVA. The size of the BSA-loaded DEX-OX8-PLA nanoparticles was in the 
range 150 to 300 nm, as measured by both DLS and NTA; a comparison of the main characteristics of 
the nanoparticles prepared using these two procedures is presented in Figure 2. Unloaded 
nanoparticles (prepared using the same protocols but without protein/peptide) were employed as 
controls (labelled in Figure 2 as ‘cNP’), 
Figure 2 
 The results indicate that the entrapment of BSA did not significantly affect the size of the particles 
formulated using either of these two techniques. Though the control nanoparticles (cNP) prepared 
using the WOW method appear to present a smaller particle size (as measured by DLS) compared to 
those prepared via the SOW technique, this was not supported by the results of the NTA 
measurements (Figure 2a). To investigate the stability of BSA-loaded nanoparticle in suspension, 
samples were measured again after 24 h (results presented in Fig 2a as DLS24), when only negligible 
agglomeration and no statistically significant difference in particle size were observed. All 
nanoparticles presented negative zeta potential values (around -30 mV, Figure 2b), indicative of the 
good overall stability observed (for comparison, the zeta potential of DEX-OX8-PLA nanoparticles 
before formulation/loading via SOW/WOW was about -20 mV). The BSA entrapment efficiency 
values are presented in Figure 2c, with the difference between the SOW and WOW methods not being 
statistically significant.  The ANG2 entrapment efficiency appeared slightly higher for the SOW 
method compared to WOW (Figure 2d), but there was no significant difference in size between the 
ANG2-loaded nanoparticles produced using the two methods. The ANG2 entrapment was found to be 
slightly lower via SOW compared to WOW (116 µg/mg). The ANG2-loaded nanoparticles presented 
zeta potential values in the range -20 to -25 mV, with those prepared by WOW being more negatively 
charged compared to those obtained via SOW (Figure 2e). SEM investigations confirmed the 
spherical morphology of DEX-OX8-PLA nanoparticles (Figure 3). 
Figure 3 
In an attempt to optimise the loading of ANG2 into DEX-OX8-PLA nanoparticles using the WOW 
technique, the effect of processing parameters on the particle size and entrapment efficiency was 
investigated. It was found that an increase in the DEX-OX8-PLA polymer concentration from 0.5% to 
1.5% (w/v) led to a significant improvement in the peptide entrapment efficiency (one way Anova 
with Tukey post hoc test; p < 0.05), with the size of the nanoparticles plateauing around 350-400 nm 
10 
Page 10 of 24
(Fig. 4a); a similar effect was previously reported for PLGA [25] when it was attributed to an increase 
in the solution viscosity with increasing polymer concentration. 
Figure 4 
Increasing the peptide concentration in the range 10-30 mg/mL significantly enlarged the particle size 
(Fig. 4b); interestingly, the entrapment efficiency reached a maximum (51%) at 20 mg/mL, followed 
by a significant drop (to 10%) when the concentration was further increased to 30 mg/mL. At the 
same time, the nanoparticle ANG2 load also decreased from 128 to 80 µg/mg. A rise in the 
concentration of the PVA surfactant gradually increased not only the entrapment efficiency but also 
the nanoparticle size (that showed a maximum for 40 mg/mL PVA; Figure 4c). In an attempt to better 
control the characteristics of the loaded nanoparticles, we also varied the speed (15,000 vs. 23,000 
rpm) and duration of the homogenisation steps (1 vs. 3 min), and found that a combination of high 
speed and longer homogenisation time resulted in high entrapment efficiency while still yielding a 
reasonably small nanoparticle size (Figure 4d). The adjusted parameters (10 mg/mL peptide; 1.5% 
w/v DEX-OX8-PLA ; 50 mg/mL PVA; stirring 23,000 rpm for 3 min) were further used to prepare 
nanoparticles loaded with either ANG2 or OP (characteristics presented in Table 1). 
The release of model peptide ANG2 from DEX-OX8-PLA nanoparticles was investigated over a 
period of four days (Figure 5a). About 50% of the model peptide was discharged within 24 h, 
followed by a gradual release (with about 90% ANG2 released over four days). 
Figure 5 
The adverse effects of the loading process on protein biological activity has been previously studied 
by Zilberman, who reported up to 18% loss of activity for complex proteins loaded via double 
emulsification [26], though small size peptides are expected to demonstrate better stability. To assess 
the potential loss of ANG2 biological activity during the nanoparticle formulation process, a 
biological assay based on the fact that ANG2 stimulates HUVEC cells to release superoxide anions 
[27] was employed. Figure 5b shows the effect of ANG2 released from DEX-OX8-PLA nanoparticles 
(loaded using the WOW method) at 0.01 µg/mL compared to that of free ANG2 at the same 
concentration, after two hours incubation. No significant difference was found in the superoxide anion 
production, indicating that the entrapment and processes do not exert a key detrimental effect on the 
bioactivity of the released ANG2. 
Figure 6 
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The cytotoxicity of ANG2-loaded DEX-OX8-PLA nanoparticles was investigated following 
incubation at different concentrations and for different periods of time with mouse brain endothelial 
cells (bEnd3), and using a typical MTT assay (living cells convert the yellow tetrazole (3-(4,5- 
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) to purple formazan, which can be quantified 
photometrically). At a concentration of 1 mg/mL, no significant differences were observed - for the 
same incubation time - between the cytotoxicity of ANG2-loaded nanoparticles and that of empty 
nanoparticles used as control (cNP), or that of the main polymeric components used in the 
formulation of the nanoparticles (PLA, DEX, and DEX-OX8); at this concentration, an apparent 
increase in the observed viability at 48 h might be explained by minor cell multiplication. The 
viability of bEnd3 cells incubated with ANG2-loaded nanoparticles was observed to significantly 
decrease with concentration (towards4 mg/mL), in particular at longer incubation times (Figure 6a). 
The cytotoxicity of DEX-OX8-PLA nanoparticles was also investigated using human brain 
endothelial cells (hCMEC/D3), which were incubated for 24 h with either empty or ANG2-loaded  
nanoparticles at 1 mg/mL concentration; no significant differences in cell viability were found 
between ANG2-loaded and unloaded nanoparticles, and the media control (Figure 6b).  
The uptake of ANG2-loaded  nanoparticles by bEnd 3 cells was confirmed by confocal microscopy 
combined with Z-stacking experiments; nanoparticles were labelled with Rhodamine B as fluorescent 
marker and are visible (in red) as agglomerates (Figure 7). 
Figure 7 
To preliminary investigate in vivo the delivery from DEX-OX8-PLA nanoformulations, and to 
confirm the ability of the optimized nanoparticle formulation process to preserve the biological 
activity of the loaded peptides, ANG2-loaded nanoparticles prepared using the WOW method were 
investigated using a trout model; as indicated by previous studies, an injection of ANG2 (50 pmol) in 
trout causes an increase in the dorsal aortic blood pressure [21]. In our experiments (Figure 8a), an 
apex of 85% in the blood pressure was reached 2-3 min after the injection, with the effect clearing 
almost completely after 30 min (5%). Following the injection of ANG2-loaded nanoparticles 
containing an equivalent amount of peptide, a similar effect was observed, although the increase in 
blood pressure was smaller than that induced by free ANG2 (reaching only 35% within 2-3 min). 
However, the effect observed was more sustained and was extended beyond the duration of the in vivo 
experiment (30 min). A two way ANOVA analysis revealed that between 5 and 25 min after the 
injection, both free and released ANG2 caused a significant increase in blood pressure, which was 
significantly higher for free ANG2. At the end of the in vivo experiment (25 min after the injection), 
the effect of the ANG2 being gradually released from nanoparticles still caused a significant increase 
in blood pressure (16%) which was not matched by that of the free ANG2 (5%). A two way ANOVA 
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test also revealed that ANG2, whether free or released from nanoparticles, did not significantly affect 
the heart rate of the tested trout (Figure 8b), confirming previous results reported in the literature [21]. 
Figure 8 
The endozepine ODN (octadecaneuropeptide) is a glial neuropeptide involved in various 
neurobiological processes such as neuroprotection [28-30] and central glucose sensing [31], and it is 
now well established that its C-terminal octaneuropeptide (ODN(11-18); OP) mimics the effects of ODN 
[19]. The intracerebroventricular (icv) injection of OP produces an anorexigenic effect in food- 
deprived mice [32] similar to that of ODN [33], however it was found that intravenous administration 
of high doses of ODN (200 fold the icv effective dose) does not affect food intake in mice, suggesting 
that these peptides do not cross the BBB [33]. Here we investigated the in vivo delivery of OP via 
DEX-OX8-PLA nanoparticulate carriers in a mice model, by monitoring the weight and food 
consumption following intravenous administration; the results were compared to those obtained using 
intravenously injected saline control.  
Figure 9 
The effect of semi-chronic (4 days) administration of OP-loaded NPs was tested by using a daily 
intravenous injection (equivalent of 10 µg of OP) in food-deprived mice. While we found the weight 
monitoring results inconclusive, and in control mice (saline) no modification in food intake was 
observed during the 4-day treatment period, intravenous administration of OP-loaded NPs provoked a 
significant reduction (P = 0.016) in food consumption during the fourth 9 h diurnal period, suggesting 
the possibility that the OP loaded into the DEX-OX8-PLA nanoparticles had been successfully 
delivered into the brain. Following cessation of treatment (days 5 and 6), animals recovered to a 
quantitative normal diet without rebound in food consumption (Figure 9). 
Conclusions 
Angiotensin II was successfully loaded as a model short peptide into octylglyceryl dextran-graft- 
poly(lactic) acid nanoparticles (DEX-OX8-PLA) using two emulsion-based formulation techniques; 
both methods afforded ANG2-loaded nanoparticles of about 250 nm size and negative zeta potential 
(approx. -30 mV, indicative of the observed good stability of the nanoformulations), with an 
entrapment efficiency of about 40%.  
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• Despite recent efforts in drug discovery leading to the development of new promising
macromolecular neuro-therapeutic agents, clinical success in delivering actives to the central
nervous system has been hindered by the inability of many macromolecules to cross the
blood-brain-barrier (BBB).
• Following from previous research results revealing the potential of modified dextran
nanoparticles to assist with drug permeation across the BBB, this work focuses on the
development of these materials for the delivery of peptides.
• Biocompatible dextran that has been modified with n-octyloxymethyloxirane and poly(lactic
acid), to increase its amphiphilic character, was used to prepare nanoparticles loaded with
bovine serum albumin, angiotensin II (ANG2) and octaneuropeptide (OP) as model
macromolecular actives.
• Both emulsification methods used for nanoparticle preparation (i.e. double emulsion and
solid/oil/water dispersion) led to the formation of nanoparticles 2-300 nm in size and having
negative zeta potential (-30 mV to -40 mV), indicative of the observed good stability of these
nanoformulations.
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DEX-OX8-PLA nanoparticles were able to sustain the release of ANG2 in vitro over more than four 
days, with almost 50% of the dose being released over the first 24 h. The results of the in vitro 
bioactivity assay using HUVEC cells indicated that the biological activity of the loaded ANG2 
peptide did not appear affected by the formulation process. This was also confirmed by the ANG2 
released from the nanoformulation following intra-arterial injection in a trout model, which produced 
a lower but more prolonged effect on the blood pressure compared to the free ANG2 control, 
suggesting a sustained release in vivo. The ANG2-loaded DEX-OX8-PLA nanoparticles were shown 
to be non-toxic against human brain endothelial cells (hCMEC/D3; 1 mg/mL), but the viability of 
mouse brain endothelial cells (bEnd3) was found to be significantly affected in particular at higher 
concentrations (up to 4 mg/mL).  
The results of in vivo studies investigating the delivery of octaneuropeptide OP from loaded DEX-
OX8-PLA nanoparticles in a mice model revealed a significant reduction in food consumption 
compared to the saline control, though without noticeable weight reduction over the duration of the 
experiment.  
Summary points: 
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• The effect of the process parameters on the nanoparticle characteristics was also investigated,
and release studies revealed a significant burst release (up to 50%), followed by
approximately 30% of the loaded model peptide (ANG2) being gradually released over one
week.
• Nanoparticles were shown to be nontoxic when tested in low concentration against human
brain endothelial cells (MTT assay), and were found to preserve the bioactivity of loaded
ANG2 as demonstrated in-vivo by experiments using a trout model.
• Nanoparticles loaded with octaneuropeptide OP were injected intravenously into food-
deprived mice, when a significant reduction in food consumption compared to the saline
control was observed.
• The results of the investigations of octylglyceryl dextran-graft-poly(lactic) acid
nanoparticles formulated by emulsification indicate their potential as non-viral
vehicles for the delivery of peptides.
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Table 1: Characteristics of DEX-OX8-PLA nanoparticles loaded with either angiotensin (ANG2) or 
octaneuropeptide (OP) using the optimised WOW method (EE - entrapment efficiency; DL - degree 
of loading). 
ANG2-loaded NPs OP-loaded NPs 
EE (%) 40.0  ± 1.4 32.2 ± 6.4 
DL (%) 48.5 ± 1.5 28.35 ± 3.1 
Size (nm) 230.0 ± 20.5 232.1 ± 1.1 
Zeta potential (mV) -35.8 ± 2.1 -26.4 ± 1.7
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Figure 1: Structure and 
1
H-NMR spectrum of the 2-[(octyloxy)methyl]oxyrane modified-dextran- 
graft-poly(lactic acid), DEX-OX8-PLA. 
Figure 2: Characteristics of DEX-OX8-PLA nanoparticles formulated using different techniques 
(WOW and SOW): (a) BSA-loaded particle size, as determined by dynamic light scattering (DLS) 
and nanoparticle tracking analysis (NTA); measurements were repeated after 24 h (DLS24) to assess 
stability; (b) zeta potential of BSA-loaded nanoparticles; (c) BSA entrapment efficiency (%); (d) 
ANG2 entrapment efficiency and ANG2-loaded nanoparticle size; (e) zeta potential of ANG2-loaded 
nanoparticles (n = 3; error bars represent SEM; WOW – water/oil/water; SOW – solid/oil/water).  
Figure 3: SEM micrographs of ANG2-loaded DEX-OX8-PLA nanoparticles prepared using WOW 
(a) and SOW (b) methods.
Figure 4: The effect of processing parameters on the peptide entrapment efficiency and on the particle 
size for the preparation of ANG2-loaded DEX-OX8-PLA nanoparticles via the WOW method: (a) 
polymer concentration; (b) ANG2 concentration  ; (c) surfactant concentration; (d) stirring speed and 
duration (n = 3; error bars represent SEM). 
Figure 5: (a) In vitro cumulative release profile of ANG2 from DEX-OX8-PLA nanoparticles; (b) 
bioactivity of ANG2 released from nanoparticles (NP ANG2) compared to free ANG2 (equivalent 
concentration, 0.01 µg/mL). n = 3 (error bars represent SEM). 
Figure 6: Viability of brain endothelial cells (as % relative to media control): (a) mouse bEnd3 cells 
incubated with either cNP or the main polymeric components (1 mg/mL), or with ANG2-loaded 
DEX-OX8-PLA nanoparticles at different concentrations, measured at different incubation time 
points; (b) human hCMEC/D3 cells incubated with ANG2-loaded DEX-OX8-PLA nanoparticles vs. 
empty DEX-OX8-PLA nanoparticles at 1 mg/ml, measured at 24 h (n = 3; error bars represent SEM). 
Figure 7: Confocal images of mouse bEnd3 cells (in green) incubated with: (A) ANG2-loaded DEX-
OX8-PLA nanoparticles that have been labelled with Rhodamine B (red); (B) media, as control (no 
nanoparticles); (C) and (D) higher magnification. 
Figure 8: The effect of intra-arterial injection of 50 pmol ANG2, equivalent ANG2 dose loaded into 
DEX-OX8-PLA nanoparticles, and a control vehicle (Ringer salt) on the dorsal aortic blood pressure 
PDA (a) and heart rate HR (b) in trout. The arrow indicates the time point when the injection was 
administered (n = 8-11; error bars represent SEM; * P < 0.05 compared to vehicle at all corresponding 
time points except for free ANG2 at 30 min). 
Figure 9: Food consumption of mice intravenously injected with OP-loaded DEX-OX8-PLA 
nanoparticles compared to saline (n = 3; error bars represent SEM). 
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